Current_JJ Consensus_NP Guidelines_NPS for_IN Treatment_NP of_IN Neurocysticercosis_NP Taenia_NP solium_NN neurocysticercosis_NN is_VBZ a_DT common_JJ cause_NN of_IN epileptic_JJ seizures_NNS and_CC other_JJ neurological_JJ morbidity_NN in_IN most_JJS developing_VBG countries_NNS ._SENT It_PP is_VBZ also_RB an_DT increasingly_RB common_JJ diagnosis_NN in_IN industrialized_JJ countries_NNS because_IN of_IN immigration_NN from_IN areas_NNS where_WRB it_PP is_VBZ endemic_JJ ._SENT Its_PP$ clinical_JJ manifestations_NNS are_VBP highly_RB variable_JJ and_CC depend_VB on_IN the_DT number_NN ,_, stage_NN ,_, and_CC size_NN of_IN the_DT lesions_NNS and_CC the_DT host_NN 's_POS immune_JJ response_NN ._SENT In_IN part_NN due_JJ to_TO this_DT variability_NN ,_, major_JJ discrepancies_NNS exist_VBP in_IN the_DT treatment_NN of_IN neurocysticercosis_NN ._SENT A_DT panel_NN of_IN experts_NNS in_IN taeniasis/cysticercosis_NN discussed_VBD the_DT evidence_NN on_IN treatment_NN of_IN neurocysticercosis_NN for_IN each_DT clinical_JJ presentation_NN ,_, and_CC we_PP present_VBP the_DT panel_NN 's_POS consensus_NN and_CC areas_NNS of_IN disagreement_NN ._SENT Overall_RB ,_, four_CD general_JJ recommendations_NNS were_VBD made_VBN :_: (_( i_NP )_) individualize_VBP therapeutic_JJ decisions_NNS ,_, including_VBG whether_IN to_TO use_VB antiparasitic_JJ drugs_NNS ,_, based_VBN on_IN the_DT number_NN ,_, location_NN ,_, and_CC viability_NN of_IN the_DT parasites_NNS within_IN the_DT nervous_JJ system_NN ;_: (_( ii_NNS )_) actively_RB manage_VB growing_VBG cysticerci_NNS either_CC with_IN antiparasitic_JJ drugs_NNS or_CC surgical_JJ excision_NN ;_: (_( iii_NNS )_) prioritize_VBP the_DT management_NN of_IN intracranial_JJ hypertension_NN secondary_JJ to_TO neurocysticercosis_NN before_IN considering_VBG any_DT other_JJ form_NN of_IN therapy_NN ;_: and_CC (_( iv_NN )_) manage_VBP seizures_NNS as_IN done_VBN for_IN seizures_NNS due_JJ to_TO other_JJ causes_NNS of_IN secondary_JJ seizures_NNS (_( remote_JJ symptomatic_JJ seizures_NNS )_) because_IN they_PP are_VBP due_JJ to_TO an_DT organic_JJ focus_NN that_WDT has_VBZ been_VBN present_JJ for_IN a_DT long_JJ time_NN ._SENT Cysticercosis_NN ,_, the_DT infection_NN caused_VBN by_IN the_DT larval_JJ stage_NN of_IN the_DT tapeworm_NN Taenia_NP solium_NN ,_, is_VBZ the_DT most_RBS common_JJ parasitic_JJ disease_NN of_IN the_DT nervous_JJ system_NN in_IN humans_NNS and_CC the_DT single_JJ most_RBS common_JJ cause_NN of_IN acquired_VBN epileptic_JJ seizures_NNS in_IN the_DT developing_VBG world_NN ,_, where_WRB prevalence_NN rates_NNS of_IN active_JJ epilepsy_NN are_VBP twice_RB those_DT in_IN developed_JJ countries_NNS ._SENT Before_IN the_DT introduction_NN of_IN modern_JJ neuroimaging_JJ diagnostic_JJ techniques_NNS ,_, knowledge_NN of_IN the_DT natural_JJ history_NN of_IN human_JJ disease_NN was_VBD limited_VBN and_CC largely_RB based_VBN on_IN cases_NNS diagnosed_VBN either_RB by_IN the_DT presence_NN of_IN subcutaneous_JJ nodules_NNS ,_, by_IN plain_JJ X-rays_NNS showing_VBG calcifications_NNS in_IN the_DT brain_NN or_CC soft_JJ tissues_NNS ,_, by_IN surgery_NN of_IN cases_NNS with_IN intracranial_JJ hypertension_NN ,_, or_CC from_IN necropsy_NN data_NNS (_( -_: ,_, ,_, )_) ._SENT The_DT image_NN of_IN an_DT aggressive_JJ ,_, lethal_JJ disease_NN arose_VBD from_IN this_DT clearly_RB biased_VBN (_( towards_IN more_JJR severe_JJ infestations_NNS )_) group_NN of_IN cases_NNS ._SENT During_IN the_DT last_JJ two_CD decades_NNS ,_, the_DT introduction_NN of_IN computed_VBN tomography_NN (_( CT_NP )_) and_CC later_RBR magnetic_JJ resonance_NN imaging_NN (_( MRI_NP )_) permitted_VBD the_DT identification_NN of_IN mild_JJ cases_NNS with_IN only_RB a_DT few_JJ parenchymal_JJ cysts_NNS ,_, and_CC the_DT terms_NNS benign_JJ and_CC malign_JJ cysticercosis_NN were_VBD coined_VBN ._SENT Later_RBR ,_, studies_NNS in_IN India_NP showed_VBD that_IN a_DT vast_JJ majority_NN of_IN single_JJ enhancing_VBG lesions_NNS ,_, until_IN then_RB attributed_VBN to_TO tuberculosis_NN ,_, were_VBD in_IN fact_NN degenerating_VBG cysticerci_NNS ._SENT The_DT introduction_NN of_IN praziquantel_NN and_CC albendazole_NN as_IN specific_JJ antiparasitic_JJ agents_NNS was_VBD enthusiastically_RB adopted_VBN by_IN many_JJ segments_NNS of_IN the_DT medical_JJ community_NN ._SENT The_DT value_NN of_IN these_DT agents_NNS has_VBZ been_VBN questioned_VBN by_IN some_DT authors_NNS (_( ,_, ,_, -_: ,_, )_) ,_, and_CC an_DT intense_JJ controversy_NN still_RB exists_VBZ ._SENT Unfortunately_RB ,_, this_DT has_VBZ led_VBN to_TO confusion_NN and_CC poorly_RB informed_VBN decisions_NNS in_IN clinical_JJ management_NN ,_, especially_RB in_IN areas_NNS where_WRB neurocysticercosis_NN is_VBZ not_RB a_DT daily_JJ diagnosis_NN ._SENT At_IN a_DT recent_JJ meeting_NN on_IN cysticercosis_NN held_VBN in_IN Lima_NP ,_, Peru_NP ,_, a_DT panel_NN of_IN experts_NNS in_IN different_JJ aspects_NNS of_IN the_DT disease_NN reached_VBD a_DT consensus_NN as_RB to_TO the_DT minimal_JJ treatment_NN guidelines_NNS for_IN neurocysticercosis_NN ._SENT Effort_NN was_VBD made_VBN to_TO identify_VB about_IN which_WDT types_NNS of_IN neurocysticercosis_NN there_EX was_VBD agreement_NN and_CC a_DT uniformly_RB accepted_VBN approach_NN ._SENT The_DT panel_NN also_RB attempted_VBD to_TO define_VB the_DT range_NN of_IN therapeutic_JJ approaches_NNS for_IN those_DT forms_NNS for_IN which_WDT there_EX was_VBD no_DT consensus_NN The_DT Parasite_NN |_SYM Taenia_NP solium_NN is_VBZ a_DT two-host_JJ zoonotic_JJ cestode_NN ._SENT The_DT adult_NN stage_NN is_VBZ a_DT 2-_CD to_TO 4-m-long_JJ tapeworm_NN that_WDT lives_VBZ in_IN the_DT small_JJ intestine_NN of_IN humans_NNS ._SENT No_DT other_JJ final_JJ hosts_NNS are_VBP known_VBN for_IN T._NP solium_NN tapeworms_NNS in_IN nature_NN ._SENT As_RB in_IN all_DT cestodes_NNS ,_, the_DT gravid_JJ proglottids_NNS at_IN the_DT terminal_JJ end_NN of_IN the_DT worm_NN are_VBP full_JJ of_IN eggs_NNS that_WDT are_VBP the_DT source_NN of_IN infection_NN with_IN the_DT larval_JJ stage_NN ,_, or_CC cysticercosis_NN ._SENT The_DT natural_JJ intermediate_JJ host_NN is_VBZ the_DT pig_NN ,_, harboring_VBG larval_JJ cysts_NNS anywhere_RB in_IN its_PP$ body_NN ._SENT Humans_NNS become_VBP infected_VBN with_IN cysts_NNS by_IN accidental_JJ ingestion_NN of_IN T._NP solium_NN infective_JJ eggs_NNS by_IN fecal-oral_JJ contamination_NN ._SENT The_DT Disease_NN |_SYM After_IN ingestion_NN of_IN Taenia_NP eggs_NNS containing_VBG infective_JJ oncospheres_NNS ,_, the_DT parasites_NNS become_VBP established_VBN in_IN the_DT tissues_NNS as_IN larval_JJ cysts_NNS and_CC reach_VB their_PP$ mature_JJ size_NN in_IN about_RB 3_CD months_NNS ._SENT The_DT parasite_NN may_MD locate_VB almost_RB anywhere_RB in_IN the_DT body_NN ._SENT The_DT infection_NN burden_NN varies_VBZ from_IN a_DT single_JJ lesion_NN to_TO several_JJ hundreds_NNS ,_, and_CC lesions_NNS may_MD range_VB in_IN size_NN from_IN a_DT few_JJ millimeters_NNS to_TO several_JJ centimeters_NNS ._SENT Laboratory_NN studies_NNS and_CC information_NN from_IN other_JJ cestodes_NNS suggest_VBP that_IN viable_JJ cysts_NNS actively_RB modulate_VBP the_DT host_NN 's_POS immune_JJ system_NN to_TO evade_VB destruction_NN by_IN it_PP ._SENT Symptomatic_JJ disease_NN results_NNS almost_RB exclusively_RB from_IN the_DT invasion_NN of_IN the_DT nervous_JJ system_NN (_( neurocysticercosis_NN )_) and_CC the_DT eye_NN and_CC is_VBZ clearly_RB different_JJ in_IN parenchymal_JJ neurocysticercosis_NN and_CC extraparenchymal_JJ neurocysticercosis_NN ._SENT The_DT usual_JJ presentation_NN of_IN parenchymal_JJ neurocysticercosis_NN is_VBZ with_IN seizures_NNS ,_, which_WDT can_MD be_VB controlled_VBN with_IN antiepileptic_JJ drug_NN therapy_NN ._SENT Occasionally_RB ,_, the_DT cysts_NNS may_MD grow_VB and_CC produce_VB a_DT mass_JJ effect_NN ._SENT Extraparenchymal_JJ infection_NN may_MD cause_VB hydrocephalus_NN by_IN mechanical_JJ obstruction_NN of_IN the_DT ventricles_NNS or_CC the_DT basal_JJ cisterns_NNS ,_, either_CC by_IN the_DT cysts_NNS themselves_PP or_CC by_IN an_DT inflammatory_JJ reaction_NN (_( ependymitis_NN and/or_CC arachnoiditis_NN )_) ._SENT The_DT so-called_JJ racemose_JJ variety_NN occurs_VBZ in_IN the_DT ventricles_NNS or_CC basal_JJ cisterns_NNS and_CC is_VBZ characterized_VBN by_IN abnormal_JJ growth_NN of_IN cystic_JJ membranes_NNS with_IN degeneration_NN of_IN the_DT parasite_NN 's_POS head_NN (_( scolex_NN )_) ._SENT These_DT cases_NNS follow_VBP a_DT progressive_JJ course_NN ,_, and_CC even_RB after_IN ventricular_JJ shunting_VBG ,_, the_DT membranes_NNS or_CC inflammatory_JJ cells_NNS and_CC proteins_VBZ frequently_RB block_VB the_DT shunt_NN ._SENT In_IN most_JJS patients_NNS ,_, neurocysticercosis_NN seems_VBZ to_TO produce_VB symptoms_NNS years_NNS after_IN the_DT initial_JJ invasion_NN of_IN the_DT nervous_JJ system_NN by_IN the_DT parasite_NN ,_, by_IN either_DT inflammation_NN around_IN the_DT parasite_NN ,_, mass_JJ effect_NN ,_, or_CC residual_JJ scarring_VBG ._SENT There_EX is_VBZ a_DT clear_JJ association_NN between_IN inflammation_NN around_IN one_CD or_CC more_JJR cysts_NNS and_CC development_NN of_IN symptoms_NNS ,_, especially_RB with_IN regard_NN to_TO seizures_NNS ._SENT The_DT natural_JJ history_NN of_IN parenchymal_JJ cysticercosis_NN has_VBZ been_VBN studied_VBN by_IN pathological_JJ examination_NN and_CC imaging_NN studies_NNS using_VBG CT_NP and_CC MRI_NP ._SENT Viable_JJ cysts_NNS are_VBP 10_CD to_TO 20_CD mm_NN in_IN diameter_NN ,_, thin-walled_JJ sacks_NNS filled_VBN with_IN clear_JJ cyst_NN fluid_NN ._SENT On_IN imaging_NN studies_NNS ,_, the_DT wall_NN is_VBZ not_RB visible_JJ and_CC the_DT fluid_NN is_VBZ isodense_NN with_IN the_DT cerebrospinal_JJ fluid_NN ._SENT There_EX is_VBZ little_JJ or_CC no_DT evidence_NN of_IN perilesional_JJ inflammation_NN ,_, and_CC they_PP do_VBP not_RB enhance_VB with_IN contrast_NN media_NNS on_IN neuroimaging_NN ._SENT As_IN the_DT parasite_NN loses_VBZ the_DT ability_NN to_TO control_VB the_DT host_NN immune_JJ response_NN ,_, an_DT inflammatory_JJ process_NN begins_VBZ ._SENT Initially_RB ,_, the_DT cysts_NNS show_VBP slight_JJ pericystic_JJ contrast_NN enhancement_NN ._SENT Later_RBR they_PP become_VBP markedly_RB inflamed_VBN and_CC edematous_JJ and_CC appear_VB as_IN ring-like_JJ or_CC nodular_JJ areas_NNS of_IN enhancement_NN after_IN the_DT injection_NN of_IN contrast_NN ._SENT This_DT phase_NN has_VBZ been_VBN called_VBN "_`` granulomatous_JJ cysticercosis_NN ,_, "_'' cysticerci_NNS in_IN encephalitic_JJ phase_NN ,_, "_'' or_CC "_`` enhancing_VBG lesions_NNS ._SENT "_'' Finally_RB ,_, the_DT cyst_NN is_VBZ processed_VBN by_IN the_DT cellular_JJ response_NN ,_, and_CC its_PP$ remnants_NNS either_CC are_VBP not_RB detectable_JJ by_IN imaging_NN or_CC become_VB calcified_VBN lesions_NNS ._SENT "_`` Giant_JJ "_'' cysts_NNS ,_, measuring_VBG more_JJR than_IN 50_CD mm_NN in_IN diameter_NN ,_, are_VBP occasionally_RB found_VBN ,_, located_VBN primarily_RB in_IN the_DT Sylvian_NP fissure_NN ._SENT Cysticercotic_JJ encephalitis_NN is_VBZ a_DT rare_JJ form_NN of_IN the_DT disease_NN in_IN which_WDT patients_NNS have_VBP numerous_JJ inflamed_VBN cysticerci_NNS ,_, leading_VBG to_TO diffuse_VB ,_, severe_JJ cerebral_JJ edema_NN ._SENT Extraparenchymal_JJ neurocysticercosis_NN includes_VBZ cysticerci_NNS in_IN the_DT ventricles_NNS and_CC basal_JJ cisterns_NNS (_( racemose_JJ cysticercosis_NN ,_, Fig._NN )_) ._SENT Since_IN the_DT cyst_NN membrane_NN is_VBZ thin_JJ and_CC the_DT fluid_NN is_VBZ isodense_NN with_IN the_DT cerebrospinal_JJ fluid_NN ,_, uninflamed_JJ extraparenchymal_JJ cysticerci_NNS are_VBP usually_RB not_RB visible_JJ on_IN CT_NP and_CC may_MD only_RB reveal_VB subtle_JJ ,_, indirect_JJ findings_NNS on_IN MRI_NP ._SENT Scans_NNS may_MD reveal_VB hydrocephalus_NN without_IN noticeable_JJ cysts_NNS ,_, ependymitis_NNS ,_, distorted_JJ basal_JJ cisterns_NNS ,_, or_CC basal_JJ meningitis_NN ._SENT Diagnosis_NN |_SYM The_DT diagnosis_NN of_IN neurocysticercosis_NN is_VBZ difficult_JJ because_IN clinical_JJ manifestations_NNS are_VBP nonspecific_JJ ,_, most_RBS neuroimaging_JJ findings_NNS are_VBP not_RB pathognomonic_JJ ,_, and_CC some_DT serologic_JJ tests_NNS have_VBP low_JJ sensitivity_NN and_CC specificity_NN ._SENT A_DT set_NN of_IN diagnostic_JJ criteria_NNS was_VBD proposed_VBN in_IN 1996_CD and_CC recently_RB revisited_VBN ,_, based_VBN on_IN objective_JJ clinical_JJ ,_, imaging_NN ,_, immunological_JJ ,_, and_CC epidemiological_JJ data_NNS ;_: these_DT criteria_NNS consist_VBP of_IN four_CD categories_NNS that_WDT are_VBP stratified_VBN according_VBG to_TO their_PP$ diagnostic_JJ strength_NN ._SENT These_DT criteria_NNS provide_VBP two_CD degrees_NNS of_IN diagnostic_JJ certainty_NN :_: definitive_JJ diagnosis_NN ,_, in_IN patients_NNS who_WP have_VBP one_CD absolute_JJ criterion_NN or_CC in_IN those_DT who_WP have_VBP two_CD major_JJ plus_CC one_CD minor_JJ and_CC one_CD epidemiologic_JJ criteria_NNS ;_: and_CC probable_JJ diagnosis_NN ,_, in_IN patients_NNS who_WP have_VBP one_CD major_JJ plus_CC two_CD minor_JJ criteria_NNS ,_, in_IN those_DT who_WP have_VBP one_CD major_JJ plus_CC one_CD minor_JJ and_CC one_CD epidemiologic_JJ criteria_NNS ,_, and_CC in_IN those_DT who_WP have_VBP three_CD minor_JJ plus_CC one_CD epidemiologic_JJ criteria_NNS ._SENT This_DT chart_NN of_IN diagnostic_JJ criteria_NNS for_IN neurocysticercosis_NN has_VBZ not_RB yet_RB been_VBN tested_VBN in_IN hospital-based_JJ studies_NNS ._SENT Differential_JJ diagnosis_NN between_IN cysticercosis_NN and_CC other_JJ parasitic_JJ diseases_NNS may_MD be_VB difficult_JJ on_IN clinical_JJ grounds_NNS ._SENT However_RB ,_, epidemiological_JJ data_NNS as_RB well_RB as_IN evidence_NN provided_VBN by_IN neuroimaging_VBG studies_NNS and_CC highly_RB specific_JJ immune_JJ diagnostic_JJ tests_NNS usually_RB provide_VBP useful_JJ diagnostic_JJ clues_NNS ._SENT Cystic_JJ hydatid_NN disease_NN almost_RB always_RB appears_VBZ on_IN CT/MRI_NP as_IN a_DT single_JJ ,_, large_JJ ,_, spherical_JJ ,_, and_CC nonenhancing_JJ intracranial_JJ cyst_NN ._SENT This_DT is_VBZ a_DT very_RB rare_JJ form_NN of_IN presentation_NN of_IN T._NP solium_NN cysticercosis_NN ._SENT Also_RB ,_, the_DT current_JJ assay_NN of_IN choice_NN ,_, immunoblot_NN ,_, does_VBZ not_RB cross-react_VB with_IN echinococcosis_NN ._SENT Other_JJ condition_NN that_WDT may_MD resemble_VB T._NP solium_NN cysticercosis_NN from_IN the_DT clinical_JJ and_CC neuroimaging_JJ points_NNS of_IN view_NN is_VBZ coenurosis_NN ,_, an_DT extremely_RB rare_JJ condition_NN caused_VBN by_IN the_DT cestode_NN Multiceps_NN multiceps_NNS ._SENT Therapeutic_JJ Alternatives_NNS |_SYM Therapeutic_JJ measures_NNS include_VBP antiparasitic_JJ drugs_NNS ,_, surgery_NN ,_, and_CC symptomatic_JJ medication_NN ._SENT Antiparasitic_JJ drugs_NNS ._SENT |_SYM As_RB demonstrated_VBN by_IN experiments_NNS in_IN animals_NNS ,_, praziquantel_NN and_CC albendazole_NN are_VBP effective_JJ antiparasitic_JJ drugs_NNS against_IN T._NP solium_NN cysticerci_NNS ._SENT Initial_JJ studies_NNS with_IN praziquantel_NP noted_VBD that_IN doses_NNS as_IN low_JJ as_IN 5_CD to_TO 10_CD mg/kg/day_NN had_VBD some_DT effect_NN against_IN cysts_NNS ,_, and_CC doses_NNS as_IN high_JJ as_IN 50_CD to_TO 75_CD mg/kg/day_NN were_VBD well_RB tolerated_VBN ._SENT A_DT dosage_NN of_IN 50_CD mg/kg/day_NN for_IN 2_CD weeks_NNS was_VBD adopted_VBN by_IN most_RBS subsequent_JJ studies_NNS (_( ,_, ,_, ,_, ,_, ,_, ,_, ,_, ,_, ,_, ,_, -_: ,_, ,_, ,_, )_) ,_, although_IN a_DT single-day_NN regimen_NN of_IN praziquantel_NN has_VBZ recently_RB been_VBN described_VBN ,_, with_IN similar_JJ rates_NNS of_IN cyst_NN disappearance_NN in_IN some_DT groups_NNS of_IN patients_NNS ._SENT No_DT dose_NN ranging_VBG studies_NNS were_VBD performed_VBN with_IN albendazole_NN in_IN cysticercosis_NN ._SENT Instead_RB ,_, the_DT dose_NN previously_RB used_VBN in_IN hydatid_NN disease_NN (_( 15_CD mg/kg/day_NN )_) was_VBD used_VBN for_IN cysticercosis_NN ._SENT The_DT initial_JJ length_NN of_IN therapy_NN was_VBD 1_CD month_NN ,_, later_RBR reduced_VBN to_TO 15_CD days_NNS and_CC 1_CD week_NN ._SENT There_EX is_VBZ limited_JJ experience_NN with_IN higher_JJR doses_NNS of_IN both_DT drugs_NNS ._SENT Between_IN 60_CD %_NN and_CC 85_CD %_NN of_IN parenchymal_JJ brain_NN cysticerci_NNS are_VBP killed_VBN after_IN standard_JJ courses_NNS of_IN treatment_NN ,_, with_IN most_JJS trials_NNS showing_VBG a_DT higher_JJR parasiticidal_JJ effect_NN of_IN albendazole_NN ._SENT Between_IN the_DT second_JJ and_CC fifth_JJ days_NNS of_IN antiparasitic_JJ therapy_NN ,_, there_EX is_VBZ usually_RB an_DT exacerbation_NN of_IN neurological_JJ symptoms_NNS ,_, attributed_VBD to_TO local_JJ inflammation_NN due_JJ to_TO the_DT death_NN of_IN the_DT larvae_NNS ._SENT For_IN this_DT reason_NN ,_, both_DT albendazole_NN and_CC praziquantel_NN are_VBP generally_RB given_VBN simultaneously_RB with_IN steroids_NNS in_IN order_NN to_TO control_VB the_DT edema_NN and_CC intracranial_JJ hypertension_NN that_WDT may_MD occur_VB as_IN a_DT result_NN of_IN therapy_NN ._SENT Praziquantel_NP interacts_VBZ with_IN steroids_NNS ,_, decreasing_VBG its_PP$ serum_NN concentrations_NNS ,_, although_IN there_EX is_VBZ no_DT evidence_NN that_IN this_DT pharmacological_JJ interaction_NN affects_VBZ its_PP$ parasiticidal_JJ properties_NNS ._SENT Serum_NN levels_NNS of_IN phenytoin_NN and_CC carbamazepine_NN may_MD also_RB be_VB lowered_VBN as_IN the_DT result_NN of_IN simultaneous_JJ praziquantel_NN administration_NN ._SENT Albendazole_NP has_VBZ better_JJR penetration_NN into_IN cerebrospinal_JJ fluid_NN ,_, its_PP$ concentrations_NNS are_VBP not_RB affected_VBN when_WRB given_VBN with_IN steroids_NNS ,_, and_CC it_PP is_VBZ cheaper_JJR than_IN praziquantel_NN ._SENT Table_NN summarizes_VBZ most_JJS trials_NNS of_IN antiparasitic_JJ therapy_NN for_IN neurocysticercosis_NN ._SENT After_IN the_DT initial_JJ descriptions_NNS of_IN successful_JJ use_NN of_IN praziquantel_NN and_CC albendazole_NN in_IN neurocysticercosis_NN ,_, several_JJ cases_NNS series_NN noted_VBD that_IN some_DT types_NNS of_IN parenchymal_JJ neurocysticercosis_NN can_MD resolve_VB on_IN imaging_NN studies_NNS without_IN being_VBG treated_VBN with_IN antiparasitic_JJ drugs_NNS ._SENT Since_IN then_RB ,_, an_DT alternative_JJ opinion_NN has_VBZ been_VBN voiced_VBN that_IN the_DT acute_JJ ,_, severe_JJ brain_NN inflammation_NN resulting_VBG from_IN their_PP$ use_NN is_VBZ unnecessary_JJ because_IN parenchymal_JJ brain_NN cysticercosis_NN follows_VBZ a_DT benign_JJ course_NN and_CC cysts_NNS will_MD degenerate_VB and_CC heal_VB by_IN natural_JJ evolution_NN of_IN the_DT disease_NN (_( ,_, ,_, -_: )_) ._SENT The_DT arguments_NNS on_IN both_DT sides_NNS of_IN the_DT discussion_NN are_VBP contrasted_VBN in_IN Table_NP ._SENT Most_RBS published_VBN studies_NNS on_IN treatment_NN of_IN neurocysticercosis_NN are_VBP uncontrolled_JJ case_NN series_NN ,_, often_RB purely_RB imaging_NN studies_NNS ._SENT The_DT main_JJ evidence_NN for_IN clinical_JJ improvement_NN after_IN antiparasitic_JJ treatment_NN of_IN parenchymal_JJ neurocysticercosis_NN is_VBZ based_VBN on_IN two_CD independent_JJ retrospective_JJ studies_NNS published_VBN in_IN 1992_CD ._SENT In_IN one_CD of_IN them_PP ,_, all_DT untreated_JJ patients_NNS (_( 49_CD of_IN 49_CD )_) had_VBD seizures_NNS in_IN the_DT follow-up_NN ,_, compared_VBN to_TO 46_CD %_NN (_( 54_CD of_IN 118_CD )_) of_IN albendazole-treated_JJ patients_NNS (_( mean_JJ follow-up_NN ,_, 3_CD years_NNS )_) ._SENT In_IN the_DT other_JJ ,_, 74_CD %_NN (_( 20_CD of_IN 27_CD )_) of_IN untreated_JJ patients_NNS had_VBD seizures_NNS in_IN the_DT follow-up_NN ,_, compared_VBN to_TO 17_CD %_NN (_( 16_CD of_IN 95_CD )_) in_IN albendazole-treated_JJ patients_NNS (_( mean_JJ follow-up_NN ,_, 2.5_CD years_NNS )_) ._SENT In_IN these_DT studies_NNS ,_, the_DT rate_NN of_IN seizure_NN recurrence_NN in_IN those_DT refusing_VBG treatment_NN was_VBD much_RB higher_JJR than_IN noted_VBN in_IN patients_NNS treated_VBN with_IN antiepileptic_JJ drugs_NNS alone_RB ._SENT The_DT increased_VBN relapse_NN rates_NNS in_IN the_DT comparison_NN group_NN could_MD be_VB explained_VBN by_IN the_DT fact_NN that_IN patients_NNS who_WP did_VBD not_RB receive_VB albendazole_NN in_IN these_DT centers_NNS were_VBD obviously_RB biased_VBN towards_IN poor_JJ compliance_NN and_CC would_MD have_VB only_RB returned_VBN to_TO the_DT hospital_NN in_IN the_DT event_NN of_IN later_JJR seizures_NNS ._SENT To_TO date_NN ,_, there_EX is_VBZ only_RB one_CD published_JJ prospective_JJ trial_NN evaluating_VBG the_DT clinical_JJ evolution_NN of_IN patients_NNS with_IN viable_JJ neurocysticercosis_NN treated_VBN with_IN antiparasitic_JJ agents_NNS compared_VBN to_TO no_DT treatment_NN ._SENT Carpio_NP and_CC colleagues_NNS studied_VBD 138_CD patients_NNS with_IN cystic_JJ neurocysticercosis_NN in_IN an_DT open-label_NN study_NN of_IN steroids_NNS alone_RB or_CC together_RB with_IN either_DT albendazole_NN or_CC praziquantel_NN ._SENT Overall_RB ,_, there_EX were_VBD no_DT significant_JJ differences_NNS in_IN the_DT proportion_NN of_IN patients_NNS free_JJ of_IN cysts_NNS at_IN 6_CD months_NNS or_CC 1_CD year_NN ,_, in_IN the_DT proportion_NN free_JJ of_IN seizures_NNS for_IN 2_CD years_NNS ,_, or_CC in_IN the_DT rates_NNS of_IN sequelae_NNS ._SENT There_EX was_VBD also_RB a_DT high_JJ rate_NN of_IN resolution_NN among_IN patients_NNS with_IN single_JJ lesions_NNS ,_, raising_VBG the_DT question_NN of_IN whether_IN patients_NNS with_IN inflamed_VBN lesions_NNS were_VBD rigorously_RB excluded_VBN from_IN that_DT trial_NN ._SENT Disappearance_NN of_IN lesions_NNS in_IN the_DT control_NN group_NN only_RB occurred_VBD in_IN cases_NNS with_IN a_DT single_JJ lesion_NN ,_, whereas_IN nearly_RB half_JJ of_IN the_DT cases_NNS that_WDT were_VBD free_JJ of_IN parasites_NNS in_IN the_DT treatment_NN arms_NNS had_VBD multiple_JJ cysts_NNS ._SENT Thus_RB ,_, this_DT study_NN ,_, while_IN not_RB demonstrating_VBG significant_JJ differences_NNS ,_, suggests_VBZ benefit_NN for_IN those_DT with_IN multiple_JJ lesions_NNS ._SENT Among_IN many_JJ case_NN series_NN (_( ,_, ,_, ,_, ,_, -_: ,_, )_) ,_, only_RB three_CD randomized_VBD ,_, controlled_VBN trials_NNS of_IN albendazole_NN have_VBP been_VBN reported_VBN on_IN patients_NNS with_IN single_JJ enhancing_VBG lesions_NNS ._SENT Two_CD studies_NNS demonstrated_VBD no_DT significant_JJ difference_NN in_IN radiographic_JJ resolution_NN ._SENT The_DT other_JJ demonstrated_VBD more_JJR rapid_JJ resolution_NN with_IN albendazole_NN but_CC no_DT significant_JJ difference_NN in_IN the_DT frequency_NN of_IN clinical_JJ events_NNS ._SENT Surgery_NN ._SENT |_SYM Prior_RB to_TO the_DT advent_NN of_IN antiparasitic_JJ drugs_NNS ,_, surgery_NN was_VBD the_DT primary_JJ therapy_NN for_IN neurocysticercosis_NN ,_, mainly_RB open_JJ surgery_NN for_IN excision_NN of_IN large_JJ cysts_NNS or_CC cysts_NNS in_IN the_DT ventricles_NNS ._SENT The_DT role_NN of_IN surgical_JJ therapy_NN in_IN the_DT management_NN of_IN neurocysticercosis_NN has_VBZ significantly_RB decreased_VBN over_IN time_NN and_CC is_VBZ now_RB mainly_RB restricted_VBN to_TO placement_NN of_IN ventricular_JJ shunts_NNS for_IN hydrocephalus_NN secondary_JJ to_TO neurocysticercosis_NN ._SENT The_DT main_JJ problem_NN in_IN these_DT cases_NNS is_VBZ the_DT high_JJ prevalence_NN of_IN shunt_NN dysfunction_NN ;_: indeed_RB ,_, it_PP is_VBZ common_JJ for_IN patients_NNS with_IN hydrocephalus_NN secondary_JJ to_TO neurocysticercosis_NN to_TO have_VB two_CD or_CC three_CD shunt_NN revisions_NNS ._SENT The_DT protracted_JJ clinical_JJ course_NN of_IN these_DT patients_NNS and_CC their_PP$ high_JJ mortality_NN rates_NNS (_( up_RB to_TO 50_CD %_NN in_IN two_CD years_NNS )_) were_VBD directly_RB related_VBN to_TO the_DT number_NN of_IN surgical_JJ interventions_NNS to_TO change_VB the_DT shunt_NN ._SENT According_VBG to_TO one_CD report_NN ,_, maintenance_NN steroid_NN therapy_NN may_MD decrease_VB the_DT frequency_NN of_IN shunt_NN blockages_NNS ._SENT Many_JJ authors_NNS advocate_VBP shunting_VBG combined_JJ with_IN antiparasitic_JJ drugs_NNS to_TO further_RBR reduce_VB the_DT incidence_NN of_IN shunt_NN failure_NN ._SENT Recently_RB ,_, less_JJR invasive_JJ procedures_NNS have_VBP been_VBN described_VBN ,_, specifically_RB the_DT use_NN of_IN neuroendoscopic_JJ resection_NN for_IN ventricular_JJ cysts_NNS ._SENT Overall_JJ results_NNS have_VBP been_VBN excellent_JJ ,_, with_IN much_RB less_JJR morbidity_NN than_IN with_IN open_JJ surgery_NN ._SENT Symptomatic_JJ and_CC anti-inflammatory_JJ medication_NN ._SENT |_SYM Corticosteroids_NNS are_VBP frequently_RB used_VBN in_IN patients_NNS with_IN neurocysticercosis_NN ._SENT The_DT most_RBS frequent_JJ regimen_NN is_VBZ dexamethasone_NN at_IN doses_NNS of_IN between_IN 4.5_CD and_CC 12_CD mg/day_NN ._SENT Prednisone_NN at_IN 1_CD mg/kg/day_NN may_MD replace_VB dexamethasone_NN when_WRB long-term_JJ steroid_NN therapy_NN is_VBZ required_VBN ._SENT Corticosteroids_NNS are_VBP frequently_RB used_VBN to_TO decrease_VB neurological_JJ symptoms_NNS due_JJ to_TO the_DT death_NN of_IN the_DT parasite_NN and_CC are_VBP the_DT primary_JJ management_NN for_IN chronic_JJ cysticercosis_NN arachnoiditis_NN or_CC encephalitis_NN ,_, where_WRB up_RB to_TO 32_CD mg_NN of_IN dexamethasone_NN per_IN day_NN is_VBZ needed_VBN to_TO reduce_VB the_DT brain_NN edema_NN accompanying_VBG this_DT condition_NN ._SENT Mannitol_NN ,_, at_IN doses_NNS of_IN 2_CD g/kg/day_NN ,_, is_VBZ also_RB used_VBN for_IN acute_JJ intracranial_JJ hypertension_NN secondary_JJ to_TO neurocysticercosis_NN ._SENT Other_JJ medications_NNS commonly_RB used_VBN to_TO treat_VB symptoms_NNS in_IN neurocysticercosis_NN patients_NNS are_VBP antiepileptic_JJ drugs_NNS and_CC analgesics_NNS ._SENT Seizures_NNS secondary_JJ to_TO neurocysticercosis_NN usually_RB respond_VB well_RB to_TO first-line_NN antiepileptic_NN ._SENT Withdrawal_NN of_IN antiepileptic_JJ drugs_NNS can_MD be_VB achieved_VBN ,_, although_IN residual_JJ calcifications_NNS on_IN CT_NP scan_NN mark_NN patients_NNS for_IN whom_WP the_DT risk_NN of_IN recurrent_JJ seizures_NNS is_VBZ high_JJ ._SENT To_TO use_VB only_RB a_DT short_JJ period_NN of_IN antiepileptic_JJ therapy_NN in_IN patients_NNS with_IN a_DT single_JJ degenerating_VBG cysticercus_NN ,_, assuming_VBG that_IN they_PP have_VBP acute_JJ symptomatic_JJ crisis_NN ,_, has_VBZ been_VBN proposed_VBN ,_, but_CC there_EX are_VBP no_DT data_NNS to_TO support_VB this_DT assumption_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Life_NP cycle_NN of_IN T._NP solium_NN Life_NN cycle_NN of_IN T._NP solium_NN ._SENT FIG.2-9_NP ._SENT |_SYM Viable_JJ cysts_NNS (_( contrasted_VBN MRI_NP ;_: Fig._NN Viable_JJ cysts_NNS (_( contrasted_VBN MRI_NP ;_: Fig._NN 2_CD )_) ,_, cyst_NN with_IN perilesional_JJ contrast_NN enhancement_NN (_( contrasted_VBN MRI_NP ;_: Fig._NN 3_CD )_) ,_, enhancing_VBG lesion_NN (_( contrasted_VBN MRI_NP ;_: Fig._NN 4_CD )_) ,_, calcifications_NNS (_( noncontrasted_VBN CT_NP ;_: Fig._NN 5_CD )_) ,_, giant_JJ cyst_NN (_( contrasted_VBN CT_NP ;_: Fig._NN 6_CD )_) ,_, cysticercotic_JJ encephalitis_NN (_( contrasted_VBN MRI_NP ;_: Fig._NN 7_CD )_) ,_, basal_JJ subarachnoid_JJ cysticercosis_NN (_( contrasted_VBN MRI_NP ;_: Fig._NN 8_CD )_) ,_, and_CC IV_CD ventricle_NN ependymitis_NN (_( contrasted_VBN MRI_NP ;_: Fig._NN 9_CD )_) ._SENT TABLE_NN 1_CD |_SYM Diagnostic_JJ criteria_NNS for_IN neurocysticercosis_NN TABLE_NP 2_CD |_SYM Studies_NNS on_IN anti-parasitic_JJ therapy_NN for_IN neurocysticercosis_NN TABLE_NP 3_CD |_SYM Arguments_NNS in_IN favor_NN of_IN and_CC against_IN antiparasitic_JJ treatment_NN for_IN neurocysticercosis_NN When_WRB the_DT panel_NN began_VBD to_TO discuss_VB the_DT preferred_JJ treatment_NN for_IN neurocysticercosis_NN ,_, it_PP immediately_RB became_VBD clear_JJ that_IN neurocysticercosis_NN is_VBZ not_RB a_DT single_JJ disease_NN for_IN which_WDT one_CD therapy_NN can_MD be_VB recommended_VBN ._SENT There_EX are_VBP marked_JJ differences_NNS in_IN clinical_JJ presentation_NN ,_, pathogenesis_NN ,_, natural_JJ history_NN ,_, and_CC treatment_NN options_NNS for_IN the_DT different_JJ forms_NNS ._SENT In_IN the_DT following_VBG sections_NNS ,_, the_DT consensus_NN and_CC disagreements_NNS of_IN the_DT panel_NN are_VBP summarized_VBN ._SENT There_EX was_VBD general_JJ agreement_NN that_IN the_DT number_NN of_IN parasites_NNS is_VBZ an_DT important_JJ factor_NN for_IN determining_VBG treatment_NN decisions_NNS ._SENT The_DT panel_NN chose_VBD to_TO categorize_VB patients_NNS as_IN those_DT having_VBG a_DT single_JJ lesion_NN ,_, a_DT few_JJ lesions_NNS ,_, moderate_JJ to_TO heavy_JJ parasite_NN loads_NNS ,_, and_CC massive_JJ infections_NNS ._SENT For_IN the_DT sake_NN of_IN clarity_NN ,_, a_DT threshold_NN of_IN five_CD or_CC fewer_JJR parasites_NNS was_VBD chosen_VBN to_TO represent_VB cases_NNS with_IN a_DT few_JJ lesions_NNS ,_, and_CC a_DT threshold_NN of_IN 100_CD parasites_NNS was_VBD chosen_VBN to_TO represent_VB massive_JJ infections_NNS ._SENT Since_IN the_DT management_NN recommendations_NNS were_VBD the_DT same_JJ for_IN patients_NNS with_IN a_DT single_JJ lesion_NN and_CC those_DT with_IN a_DT few_JJ parasites_NNS ,_, these_DT two_CD categories_NNS were_VBD later_RBR collapsed_VBN into_IN one_CD ._SENT The_DT panel_NN categorized_VBD all_DT available_JJ information_NN according_VBG to_TO level_NN of_IN quality_NN of_IN evidence_NN as_RB follows_VBZ :_: I_PP ,_, evidence_NN obtained_VBD from_IN at_IN least_JJS one_CD properly_RB randomized_VBN controlled_JJ trial_NN ;_: II-1_NP ,_, evidence_NN obtained_VBN from_IN well-designed_VBN controlled_JJ trials_NNS without_IN randomization_NN ;_: II-2_NP ,_, evidence_NN obtained_VBN from_IN well-designed_VBN cohort_NN or_CC case-control_JJ analytic_JJ studies_NNS ,_, preferably_RB from_IN more_JJR than_IN one_CD center_NN or_CC research_NN group_NN ;_: II-3_NP ._SENT evidence_NN obtained_VBD from_IN multiple_JJ time_NN series_NN with_IN or_CC without_IN the_DT intervention_NN ,_, including_VBG dramatic_JJ results_NNS in_IN uncontrolled_JJ experiments_NNS ;_: and_CC III_NP ,_, opinions_NNS of_IN respected_JJ authorities_NNS ,_, based_VBN on_IN clinical_JJ experience_NN ;_: descriptive_JJ studies_NNS and_CC case_NN reports_NNS ;_: or_CC reports_NNS of_IN expert_NN committees_NNS ._SENT The_DT information_NN provided_VBD below_RB represents_VBZ the_DT recommended_JJ management_NN for_IN patients_NNS with_IN the_DT pure_JJ forms_NNS of_IN the_DT disease_NN ._SENT Whenever_WRB there_EX was_VBD no_DT agreement_NN ,_, the_DT proposed_VBN alternatives_NNS are_VBP described_VBN as_IN positions_NNS a_DT ,_, b_NN ,_, and_CC c_LS in_IN order_NN of_IN preference_NN ,_, according_VBG to_TO the_DT number_NN of_IN experts_NNS in_IN the_DT group_NN who_WP favored_VBD each_DT option_NN ._SENT For_IN patients_NNS with_IN mixed_JJ presentations_NNS of_IN neurocysticercosis_NN ,_, a_DT consideration_NN of_IN risks_NNS and_CC benefits_NNS must_MD be_VB done_VBN to_TO choose_VB the_DT order_NN of_IN interventions_NNS ._SENT --_: GENERAL_JJ CONCEPTS_NNS :_: (_( i_NP )_) Guidelines_NNS for_IN treatment_NN of_IN neurocysticercosis_NN must_MD be_VB individualized_VBN in_IN terms_NNS of_IN number_NN and_CC location_NN of_IN lesions_NNS ,_, as_RB well_RB as_RB based_VBN on_IN the_DT viability_NN of_IN the_DT parasites_NNS within_IN the_DT nervous_JJ system_NN (_( ii_NN )_) Growth_NN of_IN a_DT parenchymal_JJ cysticercus_NN is_VBZ not_RB a_DT common_JJ event_NN and_CC may_MD be_VB life-threatening_JJ ._SENT A_DT growing_VBG parasite_NN deserves_VBZ active_JJ management_NN ,_, either_CC with_IN antiparasitic_JJ drugs_NNS or_CC by_IN surgical_JJ excision_NN ._SENT (_( iii_NP )_) In_IN patients_NNS with_IN intracranial_JJ hypertension_NN secondary_JJ to_TO neurocysticercosis_NN ,_, the_DT priority_NN is_VBZ to_TO manage_VB the_DT hypertension_NN problem_NN before_IN considering_VBG any_DT other_JJ form_NN of_IN therapy_NN ._SENT Antiparasitic_JJ drug_NN treatment_NN is_VBZ never_RB the_DT main_JJ priority_NN in_IN the_DT setting_NN of_IN elevated_JJ intracranial_JJ pressure_NN (_( iv_NN )_) Antiepileptic_JJ drugs_NNS are_VBP the_DT principal_JJ therapy_NN for_IN seizures_NNS in_IN neurocysticercosis_NN ._SENT In_IN general_JJ ,_, seizures_NNS should_MD be_VB managed_VBN in_IN a_DT similar_JJ manner_NN to_TO other_JJ causes_NNS of_IN secondary_JJ seizures_NNS (_( remote_JJ symptomatic_JJ seizures_NNS )_) ,_, since_IN they_PP are_VBP due_JJ to_TO an_DT organic_JJ focus_NN that_WDT has_VBZ been_VBN present_JJ for_IN a_DT long_JJ time_NN ._SENT However_RB ,_, after_IN resolution_NN of_IN the_DT parasitic_JJ infection_NN with_IN normalization_NN of_IN imaging_NN studies_NNS ,_, most_JJS patients_NNS who_WP are_VBP seizure-free_JJ can_MD eventually_RB discontinue_VB antiepileptic_JJ drugs_NNS ._SENT Antiparasitic_JJ drugs_NNS should_MD not_RB be_VB regarded_VBN as_IN an_DT alternative_NN for_IN antiepileptic_JJ drug_NN therapy_NN ._SENT Viable_JJ Cysts_NNS |_SYM There_EX was_VBD agreement_NN that_IN albendazole_NN and_CC praziquantel_NN are_VBP effective_JJ antiparasitic_JJ agents_NNS ,_, destroying_VBG most_JJS viable_JJ cysts_NNS ._SENT Whereas_IN there_EX was_VBD some_DT disagreement_NN with_IN regard_NN to_TO the_DT best_JJS management_NN of_IN patients_NNS with_IN few_JJ cysts_NNS ,_, in_IN patients_NNS with_IN more_JJR than_IN a_DT few_JJ parasites_NNS ,_, a_DT balance_NN of_IN risks_NNS and_CC benefits_NNS led_VBD the_DT group_NN to_TO reach_VB a_DT consensus_NN in_IN that_WDT the_DT risk_NN of_IN cyst_NN growth_NN ,_, ventricular_JJ invasion_NN ,_, or_CC multiple_JJ episodes_NNS of_IN cyst_NN degeneration_NN with_IN the_DT corresponding_JJ symptomatic_JJ periods_NNS outweighs_VBZ the_DT potential_NN (_( but_CC theoretical_JJ )_) benefits_NNS of_IN milder_JJR inflammation_NN and_CC minor_JJ scarring_VBG by_IN natural_JJ evolution_NN ._SENT The_DT majority_NN felt_VBD that_IN there_EX is_VBZ no_DT contraindication_NN for_IN the_DT simultaneous_JJ use_NN of_IN steroids_NNS ,_, but_CC one_CD expert_NN raised_VBD the_DT possibility_NN of_IN interfering_VBG with_IN the_DT clearance_NN of_IN parasite_NN remnants_NNS ._SENT Consensus_NN also_RB broke_VBD down_RP on_IN whether_IN to_TO use_VB antiparasitic_JJ drugs_NNS in_IN patients_NNS with_IN massive_JJ (_( hundreds_NNS of_IN viable_JJ cysts_NNS )_) infections_NNS ,_, mainly_RB due_JJ to_TO a_DT perception_NN of_IN high_JJ risk_NN for_IN severe_JJ side_NN effects_NNS ._SENT Enhancing_VBG Lesions_NNS |_SYM The_DT panel_NN felt_VBD that_IN patients_NNS with_IN a_DT single_JJ enhancing_VBG lesion_NN are_VBP likely_JJ to_TO do_VB well_RB with_IN antiepileptic_JJ drugs_NNS independently_RB of_IN whether_IN antiparasitic_JJ therapy_NN is_VBZ added_VBN ._SENT While_IN most_JJS panel_NN members_NNS do_VBP not_RB routinely_RB use_VB antiparasitic_JJ drugs_NNS for_IN single_JJ enhancing_VBG cysticerci_NNS ,_, some_DT felt_VBD that_IN faster_RBR radiological_JJ resolution_NN merits_NNS its_PP$ routine_JJ use_NN ,_, and_CC others_NNS felt_VBD that_IN antiparasitic_JJ drugs_NNS may_MD be_VB used_VBN in_IN selected_JJ cases_NNS ,_, i.e._FW ,_, those_DT in_IN which_WDT antiepileptic_JJ therapy_NN cannot_MD be_VB adequately_RB monitored_VBN and_CC the_DT risks_NNS of_IN adverse_JJ outcomes_NNS from_IN seizures_NNS are_VBP high_JJ ._SENT Conversely_RB ,_, for_IN patients_NNS with_IN massive_JJ infections_NNS (_( cysticercosis_NN encephalitis_NN )_) ,_, there_EX was_VBD agreement_NN that_IN they_PP should_MD not_RB be_VB used_VBN because_IN it_PP may_MD exacerbate_VB the_DT inflammatory_JJ reaction_NN in_IN the_DT brain_NN parenchyma_NN ._SENT There_EX was_VBD ,_, however_RB ,_, no_DT consensus_NN on_IN whether_IN to_TO use_VB antiparasitic_JJ drugs_NNS in_IN these_DT patients_NNS after_IN resolution_NN of_IN cerebral_JJ edema_NN ._SENT Calcifications_NNS |_SYM For_IN patients_NNS with_IN only_RB calcified_VBN lesions_NNS ,_, there_EX was_VBD also_RB consensus_NN that_IN there_EX was_VBD no_DT role_NN for_IN antiparasitic_JJ agents_NNS because_IN the_DT cysts_NNS are_VBP already_RB dead_JJ ._SENT The_DT recent_JJ description_NN of_IN contrast_NN enhancement_NN and_CC edema_NN around_IN calcified_VBN brain_NN cysts_NNS led_VBN to_TO discussion_NN of_IN whether_IN there_EX will_MD be_VB a_DT role_NN for_IN anti-inflammatory_JJ medication_NN in_IN such_JJ patients_NNS ,_, but_CC no_DT controlled_JJ data_NNS exist_VBP yet_RB ._SENT TABLE_NN 4_CD |_SYM Guidelines_NNS for_IN use_NN of_IN antiparasitic_JJ treatment_NN in_IN neurocysticercosis_NN Whenever_WRB hydrocephalus_NN or_CC intracranial_JJ hypertension_NN is_VBZ present_JJ ,_, its_PP$ management_NN should_MD be_VB the_DT first_JJ priority_NN ._SENT It_PP can_MD generally_RB be_VB managed_VBN by_IN means_NNS of_IN a_DT ventricular_JJ shunt_NN ._SENT Since_IN extraparenchymal_JJ neurocysticercosis_NN is_VBZ associated_VBN with_IN a_DT worse_JJR prognosis_NN ,_, there_EX was_VBD a_DT consensus_NN towards_IN aggressive_JJ management_NN ._SENT The_DT panel_NN felt_VBD that_IN patients_NNS with_IN cysts_NNS located_VBN in_IN the_DT ventricular_JJ system_NN should_MD be_VB treated_VBN surgically_RB ,_, especially_RB if_IN proper_JJ technology_NN for_IN neuroendoscopical_JJ resection_NN is_VBZ available_JJ ._SENT The_DT location_NN of_IN the_DT cysts_NNS and_CC the_DT presence_NN of_IN ependymitis_NNS need_VBP to_TO be_VB assessed_VBN prior_RB to_TO planning_VBG the_DT surgical_JJ approach_NN ,_, and_CC the_DT possibility_NN of_IN acute_JJ blockage_NN of_IN the_DT cerebrospinal_JJ fluid_JJ flow_NN during_IN antiparasitic_JJ treatment_NN must_MD be_VB borne_VBN in_IN mind_NN ._SENT As_RB for_IN growing_VBG parenchymal_JJ cysts_NNS ,_, a_DT warning_NN was_VBD issued_VBN for_IN basal_JJ subarachnoid_JJ cysticercosis_NN ._SENT As_RB far_RB as_RB is_VBZ known_VBN ,_, this_DT type_NN of_IN neurocysticercosis_NN is_VBZ progressive_JJ and_CC has_VBZ a_DT grim_JJ prognosis_NN ._SENT There_EX was_VBD consensus_NN that_IN cysticercosis_NN of_IN the_DT basal_JJ cisterns_NNS should_MD be_VB treated_VBN with_IN antiparasitic_JJ drugs_NNS ._SENT This_DT is_VBZ based_VBN on_IN the_DT limitations_NNS of_IN surgical_JJ resection_NN ,_, the_DT poor_JJ prognosis_NN with_IN diversion_NN procedures_NNS alone_RB ,_, and_CC case_NN series_NN that_WDT used_VBD shunting_VBG plus_IN antiparasitic_JJ drugs_NNS ._SENT The_DT optimal_JJ duration_NN of_IN antiparasitic_JJ treatment_NN for_IN this_DT type_NN of_IN lesion_NN is_VBZ not_RB known_VBN ,_, but_CC it_PP was_VBD felt_VBN that_IN therapy_NN should_MD be_VB sustained_VBN for_IN longer_JJR than_IN is_VBZ routine_JJ for_IN parenchymal_JJ disease_NN ._SENT There_EX was_VBD consensus_NN that_IN all_DT patients_NNS with_IN subarachnoid_JJ cysticercosis_NN should_MD be_VB managed_VBN with_IN corticosteroids_NNS as_IN an_DT adjunct_NN to_TO antiparasitic_JJ therapy_NN ._SENT Large_JJ (_( giant_JJ )_) cysts_NNS in_IN the_DT Sylvian_NP fissure_NN seem_VBP to_TO respond_VB well_RB to_TO corticosteroids_NNS along_IN with_IN antiparasitic_JJ drugs_NNS ._SENT Cysticercosis_NN should_MD no_RB longer_RBR be_VB considered_VBN an_DT "_`` exotic_JJ "_'' disease_NN ._SENT Besides_IN being_VBG the_DT leading_VBG cause_NN of_IN late-onset_NN seizures_NNS in_IN the_DT developing_VBG world_NN ,_, it_PP is_VBZ now_RB also_RB frequently_RB diagnosed_VBN in_IN industrialized_JJ countries_NNS because_IN of_IN increased_VBN immigration_NN from_IN areas_NNS where_WRB it_PP is_VBZ endemic_JJ ,_, with_IN over_IN 1,000_CD cases_NNS diagnosed_VBN annually_RB in_IN the_DT United_NP States_NPS alone_RB ._SENT Probably_RB the_DT best_JJS advice_NN on_IN the_DT treatment_NN of_IN neurocysticercosis_NN would_MD be_VB not_RB to_TO generalize_VB but_CC to_TO approach_VB and_CC assess_VB each_DT case_NN individually_RB ._SENT However_RB ,_, neurologists_NNS and_CC infectious_JJ disease_NN specialists_NNS who_WP are_VBP not_RB familiar_JJ with_IN the_DT disease_NN need_VBP at_IN least_JJS a_DT basic_JJ set_NN of_IN principles_NNS to_TO follow_VB ._SENT In_IN developing_VBG such_JJ principles_NNS ,_, the_DT panel_NN have_VBP tried_VBN to_TO avoid_VB the_DT trap_NN of_IN futile_JJ discussions_NNS and_CC to_TO expose_VB ,_, in_IN the_DT clearest_JJS way_NN ,_, the_DT current_JJ preferred_JJ treatment_NN options_NNS for_IN each_DT type_NN of_IN neurocysticercosis_NN ._SENT The_DT selection_NN of_IN a_DT treatment_NN option_NN must_MD include_VB in_IN the_DT consideration_NN of_IN risks_NNS and_CC benefits_VBZ the_DT economic_JJ situation_NN of_IN the_DT patient_NN ._SENT In_IN areas_NNS where_WRB neurocysticercosis_NN is_VBZ endemic_JJ ,_, where_WRB most_JJS cases_NNS are_VBP seen_VBN ,_, follow-up_NN neuroimaging_NN examinations_NNS may_MD not_RB be_VB performed_VBN for_IN economic_JJ reasons_NNS ,_, and_CC patients_NNS may_MD not_RB have_VB access_NN to_TO modern_JJ surgical_JJ techniques_NNS or_CC may_MD be_VB managed_VBN in_IN centers_NNS where_WRB intensive_JJ care_NN is_VBZ not_RB available_JJ ._SENT The_DT standard_NN of_IN care_NN will_MD change_VB ,_, but_CC still_RB the_DT best_JJS option_NN has_VBZ to_TO be_VB defined_VBN ._SENT The_DT current_JJ controversy_NN on_IN whether_IN the_DT use_NN of_IN antiparasitic_JJ agents_NNS is_VBZ of_IN benefit_NN in_IN the_DT long-term_JJ control_NN of_IN epileptic_JJ seizures_NNS in_IN neurocysticercosis_NN led_VBN to_TO much_JJ confusion_NN about_RB whether_IN such_JJ agents_NNS should_MD be_VB used_VBN in_IN any_DT form_NN of_IN the_DT disease_NN ._SENT This_DT undesirable_JJ situation_NN causes_VBZ inappropriate_JJ use_NN of_IN antiparasitic_JJ drugs_NNS ,_, i.e._FW ,_, in_IN cases_NNS with_IN already_RB calcified_VBN parasites_NNS or_CC in_IN cysticercosis_NN encephalitis_NN ._SENT Even_RB more_RBR dangerous_JJ ,_, physicians_NNS may_MD refrain_VB from_IN using_VBG antiparasitic_JJ treatment_NN when_WRB it_PP is_VBZ the_DT best_JJS treatment_NN option_NN ,_, i.e._FW ,_, for_IN a_DT growing_VBG cyst_NN ._SENT This_DT "_`` conservative_JJ "_'' therapeutic_JJ approach_NN may_MD even_RB lead_VB to_TO the_DT death_NN of_IN the_DT patient_NN if_IN the_DT period_NN of_IN inaction_NN extends_VBZ long_RB enough_RB ._SENT A_DT further_JJR conclusion_NN of_IN the_DT panel_NN was_VBD the_DT inadequacy_NN of_IN study_NN designs_NNS and_CC outcomes_NNS in_IN the_DT treatment_NN of_IN neurocysticercosis_NN ._SENT This_DT does_VBZ not_RB reflect_VB so_RB much_RB poorly_RB conducted_VBN trials_NNS (_( sometimes_RB the_DT case_NN )_) as_IN lack_NN of_IN agreement_NN that_WDT would_MD permit_VB definition_NN of_IN specific_JJ research_NN questions_NNS ,_, to_TO homogenize_VB treatment_NN groups_NNS in_IN similar_JJ trials_NNS ,_, or_CC to_TO perform_VB multicentric_JJ trials_NNS to_TO include_VB larger_JJR numbers_NNS of_IN patients_NNS with_IN similar_JJ forms_NNS of_IN neurocysticercosis_NN ._SENT The_DT inclusion_NN of_IN long-term_JJ outcomes_NNS ,_, including_VBG the_DT proportion_NN of_IN residual_JJ calcifications_NNS and_CC the_DT appearance_NN of_IN hydrocephalus_NN ,_, is_VBZ mandatory_JJ to_TO provide_VB a_DT fair_JJ evaluation_NN of_IN risk-benefit_NN analysis_NN ._SENT 